Latest Precision Therapeutics Inc. Stories
PITTSBURGH, June 6, 2011 /PRNewswire/ -- Dr. Bradley Monk of the Creighton University School of Medicine presented a new gynecologic cancer study at the 2011 American Society of Clinical Oncology (ASCO) Annual Symposium, June 5th in Chicago, Illinois.
PITTSBURGH, June 6, 2011 /PRNewswire/ -- Precision Therapeutics, Inc.
PITTSBURGH, April 7, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFxÂ®, will help further the personalization of cancer treatments.
PITTSBURGH, Jan. 19, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. will present pancreatic cancer data based on Precision's ChemoFxÂ® in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology (ASCO) GI Symposium, January 20-22 in San Francisco, California.
PITTSBURGH, June 30 /PRNewswire/ -- Precision Therapeutics, a life-science company known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, continues to gain ground in novel genomic testing and bioinformatics research.
PITTSBURGH, June 3 /PRNewswire/ -- A study demonstrating the cost savings realized through the use of the ChemoFxÂ® Drug Response Marker for assisting selection of treatment in recurrent ovarian cancer was published recently in the American Journal of Obstetrics and Gynecology (AJOG). This economic analysis of recurrent ovarian cancer patients studied the direct costs of chemotherapy for three groups; empiric, assay-assisted, and assay-adherent.
- A political dynamiter.